𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone

✍ Scribed by M. Riedel; R. Schennach-Wolff; R. Musil; S. Dehning; A. Cerovecki; M. Opgen-Rhein; J. Matz; F. Seemüller; M. Obermeier; R. R. Engel; N. Müller; H.-J. Möller; I. Spellmann

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
139 KB
Volume
25
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

To examine influencing variables of neurocognition in patients with schizophrenia and to predict cognition during antipsychotic treatment.

Methods

Data were obtained from patients with an acute episode of schizophrenia participating in two double‐blind and one open label trial comparing the effects of different atypical antipsychotics on cognition. In total, 129 patients were enrolled in this analysis. Cognitive function was assessed at admission, week 4 and 8. Efficacy and tolerability were assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and the Simpson Angus Sale (SAS). Patients were treated with aripirazole, olanzapine, quetiapine and risperidone. Regression analysis including mixed effect models was performed.

Results

A significant improvement in all cognitive domains was observed from baseline to week 8. Regarding the antipsychotic treatment applied quetiapine seemed to achieve the most favourable cognitive improvement. Negative and depressive symptoms, the patient's age and the concomitant and antipsychotic treatment applied were observed to significantly influence and predict neurocognition.

Conclusion

The results may indicate that schizophrenia is a static disorder with trait and state dependent cognitive components especially in the memory domains. The influence of negative and depressive symptoms should be considered in daily clinical routine. Copyright © 2010 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Effectiveness of antipsychotic polypharm
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
✍ Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner. ## Methods In this open‐label study, 17 patients with treatment‐refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and ris

A preliminary study of the comparative e
A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia
✍ Yang-Tae Kim; Byung-Jo Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

## Abstract The aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia. The subjects were schizophrenic outpatients, all meeting DSM‐IV diagnostic criteria for schizophrenia and already treated with risperidone. In the experi

Quetiapine versus olanzapine for the tre
Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia
✍ Pinkhas Sirota; Irit Pannet; Ady Koren; Eleonora Tchernichovsky 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych

A comparison of the efficacy and safety
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration
✍ C. W. Ritchie; E. Chiu; S. Harrigan; S. Macfarlane; M. Mastwyk; G. Halliday; H. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect

An observational study of the effectiven
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder
✍ Franca Centorrino; Adam L. Meyers; Jonna Ahl; Stephanie L. Cincotta; Leslie Zun; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## Objective To determine the effect of intramuscular (IM) olanzapine in severely agitated patients. ## Methods This was an open‐label multicenter 1‐week observational study of IM olanzapine treatment in severely agitated inpatients and psychiatric emergency services with bipolar man